KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1
Open Access
- 23 November 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 9 (2) , 156-169
Abstract
Blockade of the PD1 pathway is a broadly effective cancer therapy, but additional immune-inhibitory pathways contribute to tumor immune evasion. HERV–H LTR-associating 2 (HHLA2; also known as B7H5 and B7H7) is a member of the B7 family of immunoregulatory ligands that mediates costimulatory effects through its interaction with the CD28 family member transmembrane and immunoglobulin domain containing 2 (TMIGD2). However, HHLA2 has also been known to have inhibitory effects on T cells. Here, we report that we have identified killer cell immunoglobulin-like receptor, three immunoglobulin domains and long cytoplasmic tail 3 (KIR3DL3) as an inhibitory receptor for HHLA2 in T cells and natural killer (NK) cells and have generated HHLA2 and KIR3DL3 antibodies that block the immune-inhibitory activity of HHLA2, preserving the costimulatory signal. It is known that HHLA2 is frequently expressed in several tumor types, including clear cell renal cell carcinoma (ccRCC). We found that HHLA2 expression was nonoverlapping with PDL1 expression in ccRCC, suggesting that HHLA2 mediates a mechanism of tumor immune evasion that is independent from PDL1. Blockade of both the PD1 and KIR3DL3 pathways may be a more effective way to reverse tumor immune evasion.See related Spotlight on p. 128Keywords
All Related Versions
Funding Information
- NIH (R01 CA196996)
- NIH (P50 CA101942-12)
- NIH (P50CA206963)
- NIH (AI056299)
- U.S. Army Medical Research Acquisition Activity (MD 21702-5014)
- U.S. Department of War (KC170139)
This publication has 49 references indexed in Scilit:
- B7-H5 costimulates human T cells via CD28HNature Communications, 2013
- Blocking IDO activity to enhance anti-tumor immunityFrontiers in Bioscience-Elite, 2012
- Blocking IDO activity to enhance anti-tumor immunityFrontiers in Bioscience-Elite, 2012
- Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen BNature, 2011
- Molecular characterization of KIR3DL3Immunogenetics, 2006
- PD‐1 inhibits T‐cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθFEBS Letters, 2004
- The B7–CD28 superfamilyNature Reviews Immunology, 2002
- Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytesInternational Immunology, 1996
- Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.Journal of Experimental Medicine, 1992
- In vitro regulation of immunoglobulin synthesis by T-cell subpopulations defined by a new human T-cell antigen (9.3)Cellular Immunology, 1982